Can umbilical cord blood keep leukemia at bay in older patients?

NCT ID NCT07761702

Not yet recruiting Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding an umbilical cord blood infusion to standard consolidation chemotherapy can help older adults with intermediate- or high-risk acute myeloid leukemia (AML) stay free of relapse. About 132 patients aged 60 to 80 who achieved remission after initial treatment will be randomly assigned to receive either cord blood plus chemo or chemo alone, followed by maintenance therapy. The main goal is to see if the cord blood approach improves leukemia-free survival at two years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Unrelated umbilical cord blood infusion combined with decitabine, cytarabine, and azacitidine
What this could lead to: If successful, this approach could offer a new consolidation strategy to reduce relapse and improve survival in older AML patients who have limited treatment options.
What could go wrong: This is a randomized trial, but cord blood infusion carries risks like graft failure, infection, and immune reactions. Results may not apply to all AML subtypes, and the benefit over standard chemo is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOGENOUS LEUKEMIA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML (ACUTE MYELOGENOUS LEUKEMIA)

More trials for these conditions

Other studies related to the condition(s) this trial covers.